Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. The antibody-drug conjugate (ADC) Inotuzumab ozogamicin, sold under the brand name Besponsa, is a targeted cancer therapeutics used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This ADC drug is a conjugate that combines a monoclonal antibody Inotuzumab with a cytotoxic agent called calicheamicin through linker. This biosimilar antibody is used for research only. MW: 144.78 kD.
Product Details |
Species Reactivity | Human |
---|
Host/Isotype | Human IgG4 |
---|
Class | Monoclonal |
---|
Type | Recombinant Antibody |
---|
Immunogen | Human CD22 |
---|
Clone | Inotuzumab biosimilar |
---|
Conjugate | Unconjugated |
---|
Purity | 99% |
---|
Molecular Weight | 144.78 kD |
---|
Protein Concentration | 1mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100mM Pro-Ac, 20mM Arg-Ac, pH 5.0 |